文献速递前列腺癌

穿刺未检出的筛状和导管内前列腺癌与不良结局相关

Undetected Cribriform and Intraductal Prostate Cancer at biopsy is associated with adverse outcomes.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-10-21

研究纳入2015年1月至2022年12月行根治性前列腺切除术的836例患者,评估穿刺对导管内癌(IDC)和筛状结构(Crib)假阴性对肿瘤学结局的影响。假阴性穿刺者病理分期≥pT3率为56.8%,真阴性者为28.1%(p<0.001);多因素Cox分析显示假阴性穿刺与生化复发风险升高独立相关(HR 2.14,95%CI 1.41-3.25;p<0.001)。

要点

  • 穿刺对IDC/Crib假阴性者病理分期≥pT3率为56.8%,真阴性者为28.1%(p<0.001)。
  • 假阴性穿刺与生化复发风险升高独立相关(HR 2.14,95%CI 1.41-3.25;p<0.001)。
  • 术前log PSA(HR 2.07)和阳性针数≥33%(HR 1.68)也与生化复发风险升高相关。

核心结论

  • 与真阴性穿刺相比,穿刺对IDC/Crib假阴性独立与更高的生化复发风险和更晚的病理分期相关。

研究设计与样本

  • 研究纳入2015年1月至2022年12月期间行根治性前列腺切除术的患者,共836例。
  • 采用多因素Cox比例风险模型分析生化失败预测因素。

主要发现

  • 836例患者中,233例(27.9%)穿刺有Crib,125例(15.0%)有IDC,71例(8.5%)同时有IDC和Crib。
  • 关于穿刺IDC/Crib状态,217例(26%)为假阴性,332例(39.7%)为真阴性,256例(30.6%)为真阳性,24例(3.7%)为假阳性。
  • 假阴性穿刺者病理分期≥pT3率为56.8%,真阴性者为28.1%(p<0.001)。
  • 多因素Cox分析显示,术前log PSA(HR 2.07,95%CI 1.53-2.82;p<0.001)、穿刺阳性针数≥33%(HR 1.68,95%CI 1.07-2.63;p=0.024)和IDC/Crib假阴性穿刺(HR 2.14,95%CI 1.41-3.25;p<0.001)均与生化复发风险升高显著相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intraductal carcinoma (IDC) and cribriform pattern (Crib) of prostate cancer are increasingly recognized as independent prognosticators of poor outcome, both in prostate biopsies and radical prostatectomy (RP) specimens. OBJECTIVE: The aim of our project is to assess the impact of false negative biopsies for these two characteristics on oncological outcomes. MATERIAL AND METHODS: Patients who underwent RP between January 2015 and December 2022 were included in the study. Predictors of Biochemical Failure were examined using a multivariate Cox proportional hazards model. RESULTS AND LIMITATION: Among the 836 patients who underwent RP, 233 (27.9%) had Crib, and 125 (15.0%) had IDC on prostate biopsy, with 71 (8.5%) patients having both IDC and Crib. Concerning IDC/Crib status at biopsy, 217 (26%) patients had a false-negative biopsy, 332 (39.7%) had a true-negative biopsy, 256 (30.6%) showed a true-positive biopsy, and 24 (3.7%) exhibited a false-positive biopsy, with respect to either pattern. When comparing false-negative, false-positive, true-negative and true-positive biopsies for IDC/Crib, we found that patients with a false-negative biopsy for IDC/Crib versus those with a true-negative biopsy for IDC/Crib disclosed a rate of advanced pathological stage (≥pT3) which was twice that of patients with a true-negative biopsy for IDC/Crib: 56.8% versus 28.1%, respectively (p < 0.001). On multivariate Cox analysis, log PSA before RP (hazard ratio [HR] 2.07, 95% CI 1.53-2.82; p < 0.001), a higher percentage of positive cores at biopsy ( ≥ 33%) (HR 1.68, 95% CI 1.07-2.63; p = 0.024), and false negative biopsy for IDC/Crib (HR 2.14, 95% CI 1.41-3.25; p < 0.001), were each significantly associated with an increased risk of BCR. CONCLUSIONS: A false-negative biopsy for IDC/Crib is independently associated with higher risk of BCR and advanced pathological stage compared to a true negative biopsy.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Bernardino RM, Yin LB, Lajkosz K, et al. Undetected Cribriform and Intraductal Prostate Cancer at biopsy is associated with adverse outcomes. Prostate Cancer Prostatic Dis. 2024. PMID: 39433886. doi:10.1038/s41391-024-00910-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。